Lund, Sweden, 08.00 CET, 5 March 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces that it will present at the Canaccord Musculoskeletal Conference on Tuesday 6 March at 10.00 am EST in New Orleans, US
Patrick O’Donnell, General Manager & Executive Vice President of Commercial Operations US, will present at the Conference. His presentation will provide an overview of the Company’s proprietary CERAMENT platform and its products which provide clear benefits to patients, surgeons and payors through their ability to remodel to host bone and to protect the healing process from infection in the case of CERAMENT® G&V*. Reducing infection rates in orthopedic surgery is a key objective in order to decrease the patient’s length of stay and the number of readmissions following the primary procedure.
The presentation will also cover recent progress made with the Company’s growth strategy which is focused on driving the sales of BONESUPPORT’s currently marketed products, generating further clinical data to drive their adoption in major indications such as trauma and revision arthroplasty and completing the FORTIFY study which is designed to support a planned Premarket Approval (PMA) filing with CERAMENT G in 2020.
BONESUPPORT™ intends to have a number of one on one investor meetings at the Canaccord Musculoskeletal Conference.
BONESUPPORT™ will also be exhibiting at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting, which takes place from 6-10 March in New Orleans, US.
BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.
BONESUPPORT’s marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary CERAMENT technology platform.
The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.
BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%. The Company’s financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.
The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.
BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at bonesupport.com
*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States
BONESUPPORT™ and CERAMENT® are registered trademarks.
For more information contact:
Björn Westberg, CFO
+46 (0) 46 286 53 60
Citigate Dewe Rogerson
Pip Batty, David Dible, Shabnam Bashir, Isabelle Andrews
+44 (0)20 7282 1022